Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 1
2009 1
2010 1
2011 2
2014 2
2015 2
2016 3
2017 2
2018 2
2019 1
2020 1
2021 2
2022 4
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

25 results

Results by year

Filters applied: . Clear all
Page 1
PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
van Amerongen RA, Tuit S, Wouters AK, van de Meent M, Siekman SL, Meeuwsen MH, Wachsmann TLA, Remst DFG, Hagedoorn RS, van der Steen DM, de Ru AH, Verdegaal EME, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: van der steen dm. Front Immunol. 2023 Mar 21;14:1121973. doi: 10.3389/fimmu.2023.1121973. eCollection 2023. Front Immunol. 2023. PMID: 37026005 Free PMC article.
Broadly applicable TCR-based therapy for multiple myeloma targeting the immunoglobulin J chain.
Meeuwsen MH, Wouters AK, Wachsmann TLA, Hagedoorn RS, Kester MGD, Remst DFG, van der Steen DM, de Ru AH, van Hees EP, Kremer M, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: van der steen dm. J Hematol Oncol. 2023 Feb 27;16(1):16. doi: 10.1186/s13045-023-01408-6. J Hematol Oncol. 2023. PMID: 36850001 Free PMC article.
WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma.
van Amerongen RA, Hagedoorn RS, Remst DFG, Assendelft DC, van der Steen DM, Wouters AK, van de Meent M, Kester MGD, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. van Amerongen RA, et al. Among authors: van der steen dm. J Immunother Cancer. 2022 Jun;10(6):e004409. doi: 10.1136/jitc-2021-004409. J Immunother Cancer. 2022. PMID: 35728869 Free PMC article.
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia.
van der Lee DI, Reijmers RM, Honders MW, Hagedoorn RS, de Jong RC, Kester MG, van der Steen DM, de Ru AH, Kweekel C, Bijen HM, Jedema I, Veelken H, van Veelen PA, Heemskerk MH, Falkenburg JHF, Griffioen M. van der Lee DI, et al. Among authors: van der steen dm. J Clin Invest. 2019 Feb 1;129(2):774-785. doi: 10.1172/JCI97482. Epub 2019 Jan 14. J Clin Invest. 2019. PMID: 30640174 Free PMC article.
Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.
Bijen HM, van der Steen DM, Hagedoorn RS, Wouters AK, Wooldridge L, Falkenburg JHF, Heemskerk MHM. Bijen HM, et al. Among authors: van der steen dm. Mol Ther. 2018 May 2;26(5):1206-1214. doi: 10.1016/j.ymthe.2018.02.017. Epub 2018 Feb 23. Mol Ther. 2018. PMID: 29567312 Free PMC article.
A broad and systematic approach to identify B cell malignancy-targeting TCRs for multi-antigen-based T cell therapy.
Meeuwsen MH, Wouters AK, Jahn L, Hagedoorn RS, Kester MGD, Remst DFG, Morton LT, van der Steen DM, Kweekel C, de Ru AH, Griffioen M, van Veelen PA, Falkenburg JHF, Heemskerk MHM. Meeuwsen MH, et al. Among authors: van der steen dm. Mol Ther. 2022 Feb 2;30(2):564-578. doi: 10.1016/j.ymthe.2021.08.010. Epub 2021 Aug 8. Mol Ther. 2022. PMID: 34371177 Free PMC article.
A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
de Rooij MAJ, Remst DFG, van der Steen DM, Wouters AK, Hagedoorn RS, Kester MGD, Meeuwsen MH, Wachsmann TLA, de Ru AH, van Veelen PA, Verdegaal EME, Falkenburg JHF, Heemskerk MHM. de Rooij MAJ, et al. Among authors: van der steen dm. Mol Ther Oncolytics. 2022 Dec 2;28:1-14. doi: 10.1016/j.omto.2022.11.007. eCollection 2023 Mar 16. Mol Ther Oncolytics. 2022. PMID: 36589698 Free PMC article.
Healthy cells functionally present TAP-independent SSR1 peptides: implications for selection of clinically relevant antigens.
de Waard AA, Verkerk T, Hoefakker K, van der Steen DM, Jongsma MLM, Melamed Kadosh D, Bliss S, de Ru AH, Admon A, van Veelen PA, Griffioen M, Heemskerk MHM, Spaapen RM. de Waard AA, et al. Among authors: van der steen dm. iScience. 2021 Jan 9;24(2):102051. doi: 10.1016/j.isci.2021.102051. eCollection 2021 Feb 19. iScience. 2021. PMID: 33554062 Free PMC article.
Erratum: A library of cancer testis specific T cell receptors for T cell receptor gene therapy.
de Rooij MAJ, Remst DFG, van der Steen DM, Wouters AK, Hagedoorn RS, Kester MGD, Meeuwsen MH, Wachsmann TLA, de Ru AH, van Veelen PA, Verdegaal EME, Falkenburg JHF, Heemskerk MHM. de Rooij MAJ, et al. Among authors: van der steen dm. Mol Ther Oncolytics. 2023 Oct 23;31:100738. doi: 10.1016/j.omto.2023.100738. eCollection 2023 Dec 19. Mol Ther Oncolytics. 2023. PMID: 37920174 Free PMC article.
25 results